Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Date:6/2/2008

var s=s_gi(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >AEZS; TSX: AEZ) in the United States, Canada and Mexico.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for KRX-0401, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward- looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully c
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
2. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
3. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
4. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
5. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
6. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
7. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
8. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
9. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
10. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
11. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... SAN DIEGO, July 31, 2014 Tandem Diabetes Care®, ... and manufacturer of the t:slim® Insulin Pump, today reported its ... In comparing the second quarter of 2014 to ... percent to $10.3 million from $5.5 million , t:slim ... pumps In comparing six months ended June 30, ...
(Date:7/31/2014)... , July 31, 2014  Alexza Pharmaceuticals, Inc. ... update on its pipeline and new product development ... to initiate a Phase 2a study of AZ-002 ... for the management of patients with acute repetitive ... Staccato -based product candidates for development - AZ-008 ...
(Date:7/31/2014)... July 31, 2014  Decision Resources Group is launching ... product Marketrack to now include ChinaTrack; the new capabilities ... in an interactive dashboard providing detailed brand-level share tracking ... a hospital level. Other key capabilities of ... feed: In addition to end-user surveys of healthcare facilities, ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
(Date:7/31/2014)... July 31, 2014 Bedford Commons ... firm Innerspire: Brand ReEnergizers to do what ... how we connect with the community all while still ... area practice, which caters to women’s health needs for ... and total women focused care ( Gynecology ), worked ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Dr. Andrew ... American Board of Dermatology, fellowship trained Mohs surgeon that ... Top Docs. , After extensive dermatology research training at ... Health, Dr. Li completed his internship in internal medicine ... University of Pennsylvania in Philadelphia. Dr. Li pursued further ...
(Date:7/31/2014)... has been rising steadily in the U.S in recent ... and Health, the number of individuals reporting past year ... (669,000). Emerging evidence suggests the increase may be linked ... and/or intranasal PO use to heroin use, with POs ... heroin injection. This drug-use trajectory appears to have ...
(Date:7/31/2014)... 2014 Model moms are believers. PBS has ... positions in the field have grown exponentially in the last ... thriving industry, there are associated myths that need to be ... Frontier Nursing University . Celebrating 75 years in 2014, ... in the nation. “Frontier is changing the face of ...
(Date:7/31/2014)... Infection prevention and control is the ... products in the pharma, medical device, and food industries. ... products and equipment types; the two procedures prevent the ... products. , The world market for infection prevention ... a CAGR of about 7.5% through to 2018. The ...
Breaking Medicine News(10 mins):Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 2Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 3Health News:Doctor Videos & Women’s Stories Jumpstart Local OB-GYN Practice 4Health News:NJ Top Docs Proudly Presents Approved Provider, Dr. Andrew Li of Warren Skin Care Center 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 3Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 2Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 3Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 4Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 5Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 2Health News:Infection Prevention and Control Market to Post about 7.5% CAGR through 2018, States Infiniti Research in Its Study Published at MarketPublishers.com 3
... from across Pennsylvania with substantial experience in ... Sept. 11 The Pennsylvania,Patient Safety Authority,s Board ... control experts to help implement Act 52 of ... Ed Rendell in July to help reduce and,eliminate ...
... Sally Watkins, PhD(c), MS, RN, has been named ... the Washington State Nurses,Association (WSNA), the State,s oldest ... are very fortunate to have in Sally Watkins ... and nurse advocate," said WSNA Executive,Director Judy Huntington, ...
... a mid-August edition of Circulation: Journal of the America Heart ... eating habits, it can strongly influence their heart disease risk ... Coronary Risk Factor Intervention Project have landmark implications on how ... a childs fat intake, primarily reduction in intake of saturated ...
... power industry is riding the green wave back into ... to our growing energy needs. But even as the ... play, it is bound by a global energy landscapefrom ... the marketplace. , Veteran New York Times energy ...
... shows no improvement with carvedilol , , TUESDAY, Sept. 11 (HealthDay News) ... that has been effective for adults with heart failure, did not ... rate of improvement -- and the lack of it -- was ... drug as it was for 54 youngsters who got a placebo. ...
... of prostate biopsies resulted in a cancer diagnosis among ... first biopsy did not find cancer often had multiple ... a cancer diagnosis. , While PSA (prostate-specific antigen) ... a biopsy is what actually determines the presence of ...
Cached Medicine News:Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 2Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 3Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 4Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 5Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 6Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 7Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 8Health News:Patient Safety Authority Board of Directors Names Infection Advisory Panel 9Health News:New Director of Nursing Practice Named for Nurses Association 2Health News:Children who learn heart healthy eating habits lower heart disease risk 2Health News:Children who learn heart healthy eating habits lower heart disease risk 3Health News:Trade-offs reveal no clear favorites in alternative energy market 2Health News:Beta Blocker Doesn't Help Children With Heart Failure 2Health News:Other highlights in the September 11 JNCI 2Health News:Other highlights in the September 11 JNCI 3
Remote Alpha Dock system for the DNA Engine line, allows, Alpha unit to function remotely (requires fan power supply)...
Reads single TrakMates tubes instantly, and drops decoded tube number instantly into any Windows application. System includes reader and Windows based software....
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
... acrylic panels mounted on powder-coated ... a free-standing modular cleanroom that ... 3. Optional ceiling HEPA filter/fan ... configured to customer requirements. Negative-pressure ...
Medicine Products: